Compare Dominion Energy Inc (D) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Dominion Energy (D) trades at $61.75, down 0.4% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 EPS of $0.79 versus $0.681 expected, continuing a pattern of exceeding expectations. Fundamentals show improving revenue growth to $16.51B in 2025 and net income margin expansion to 13.99%, though cash flow trends show significant capital investments. The pending merger with NextEra Energy dominates recent news coverage, with regulators reviewing a proposed $1 billion annual Virginia supplier program.

Dominion Energy presents a mixed investment case with solid fundamental performance offset by technical weakness and merger execution risks. The stock trades below analyst consensus target of $71.56, offering potential upside if the NextEra merger proceeds smoothly. Key risks include regulatory approval uncertainty, high capital expenditure requirements, and interest rate sensitivity given the company's substantial debt load of $37.31B long-term.

INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.

The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.